RCUS

Arcus Biosciences, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$17.77

Price (1 Year)

$31 $17.77

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %5.6 / %30
Non-compliant assets / Total market cap %37.8 / %30
Non-compliant revenue / Total income %34.3 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Website

Analysis (Turkish): RCUS Hissesi Caiz mi, Helal mi? Arcus Biosciences, Inc. Katılım Analizi